3D Cell Culture Market Size, Share & Trends Analysis Report By Technology (Scaffold Based, Scaffold Free, Bioreactors, Microfluidics, Bioprinting), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
3D Cell Culture Market Growth & Trends
The global 3D cell culture market size is anticipated to reach USD 3.21 billion by 2030 and is anticipated to expand at a CAGR of 11.22% during 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by technological advancements in in-vitro testing models, a rising focus on personalized medicine, and supportive government legislation for R&D. Moreover, the increasing prevalence of chronic disorders, and the growing significance of cell therapies in their treatment have created momentum for industry expansion.
Tissue engineering has made significant developments in creating 3D culture models that mimic the in-vivo culture media more precisely than the conventional 2D cell cultures. This resulted in increased utilization of 3D cell culture systems for toxicity testing, drug discovery, and regenerative medicine development. Also, recent product launches from industry players have supported market growth to a significant extent. For instance, in June 2023, Pixelgen Technologies launched its first molecular pixelation kit for 3D spatial study of proteins present on cell surface.
In addition, the development of advanced technologies like microfluidics, bioprinting, and high-content screening systems, has leveraged the capabilities of these models. These technologies allow excellent control over culture conditions, cell organization, and the capability to perform high-efficiency screening, thereby fueling the utilization of 3D culture systems. Moreover, increased collaboration between market players to utilize bioprinting and microfluidics techniques in developing culture models has propelled market growth. For instance, in June 2023, AIM Biotech and MatTek partnered together to offer innovative idenTX and organiX microfluidic 3D tissue culture platforms along with complete drug discovery research services in specific areas of neurobiology, immune-oncology, and vascular biology.
3D cultures can closely replicate the typical microarchitecture and morphology of organs and hence are continuously developed for studies that require in vivo models to analyze the effect of a drug over body tissues and organs. This factor, coupled with the availability of several choices in terms of the material and structure of the scaffold for a variety of in-vitro applications, is anticipated to boost revenue generation for scaffolds. Recent research has explored the use of a broad range of scaffolds, such as graphene scaffolds, nanofibers, natural marine collagen, freeze-casting, and others. In addition, emerging applications of techniques such as lab-on-a-chip in several assay types, including proliferation, stimulation, viability, transport, high content screening, patch clamping, and metabolic activity are anticipated to lead to an increase in demand for advanced and efficient solutions.
However, the lack of consistency in 3D cell model products is one of the major drawbacks that is expected to hinder the growth of the market. Moreover, various factors such as variability in cell culture, standardized challenges, scale & manufacturing issues, and quality control issues might hamper the market growth.
3D Cell Culture Market Report Highlights
- The scaffold-based technology segment dominated the market in 2023 with a revenue share of 48.94% and is attributed to the increasing application of scaffold-based cultures in tissue engineering and regenerative medicine applications
- Stem cell research & tissue engineering held the largest share in 2023, whereas the cancer institute segment is expected to witness the fastest growth owing to the rising prevalence of cancer, and the benefits offered by 3D cell cultures in cancer research
- In the end-use segment, biotechnology and pharmaceutical companies dominated the market with a revenue share in 2023. The higher revenue growth is attributed to the continuous growth and commercial success of biopharmaceuticals coupled with the expanding portfolio of the major pharmaceutical companies
- North America region dominated the global market in 2023 with a revenue share of 38.97%, owing to the presence of advanced healthcare infrastructure, developed economies, the presence of key players, and various strategic initiatives undertaken by them
Please note The report will be delivered in 2-3 business days upon order notification.